Skip to main content
. 2023 Jan 25;136(2):jcs260391. doi: 10.1242/jcs.260391

Fig. 5.

Fig. 5.

CCDC86 expression is regulated by MYCN and represents a prognostic marker for neuroblastoma patients. (A) Kaplan–Meier curve (survival probability in months) of neuroblastoma patients expressing low (red curve) or high (blue curve) levels of CCDC86. (B) CCDC86 expression levels in neuroblastoma patients with (red) and without (green) MYCN amplification (Kocak cohort). (C) CCDC86 expression levels in neuroblastoma patients with different stages (st) of cancer (Kocak cohort). (D) CCDC86 expression levels in neuroblastoma patients with (red) and without (grey) MYCN amplification (SEQC cohort). (E) CCDC86 expression levels in neuroblastoma patients with different stages of cancer (SEQC cohort). In B–E, the numbers indicate the sample sizes. (F) MYCN chromatin immunoprecipitation sequencing profiles at the CCDC86 locus in different neuroblastoma cell lines. (G) qPCR analyses of MYCN and CCDC86 expression in TET21-N cells without (0) (light blue bars) and with 24 h doxycycline (DOX) treatment (red bars). The data represent the average of three independent experiments. Error bars indicate the s.d. Datasets were analysed by a two-tailed unpaired Student's t-test. ***P<0.0001.